<DOC>
	<DOCNO>NCT02798471</DOCNO>
	<brief_summary>This event drive Phase 3 , prospective , randomize , open-label , blind endpoint evaluation ( PROBE ) parallel group study subject confirm VTE . This study design evaluate pharmacokinetics ( PK ) pharmacodynamics ( PD ) edoxaban compare efficacy safety edoxaban standard care pediatric subject confirm VTE .</brief_summary>
	<brief_title>Hokusai Study Pediatric Patients With Confirmed Venous Thromboembolism ( VTE )</brief_title>
	<detailed_description>The objective demonstrate non-inferiority edoxaban standard care ( SOC ; include low molecular weight heparin ( LMWH ) , vitamin K antagonist ( VKA ) , synthetic pentasaccharide ( SP ) Xa inhibitor ) treatment secondary prevention VTE pediatric subject regard composite efficacy endpoint ( ie , symptomatic recurrent VTE , death result VTE , change extension thrombotic burden ) first 3-month treatment period .</detailed_description>
	<mesh_term>Thrombosis</mesh_term>
	<mesh_term>Thromboembolism</mesh_term>
	<mesh_term>Embolism</mesh_term>
	<mesh_term>Venous Thromboembolism</mesh_term>
	<mesh_term>Pulmonary Embolism</mesh_term>
	<mesh_term>Venous Thrombosis</mesh_term>
	<mesh_term>Fondaparinux</mesh_term>
	<mesh_term>Edoxaban</mesh_term>
	<mesh_term>Heparin</mesh_term>
	<criteria>1 . Male female pediatric subject birth ( defined 38 week gestational age ) less 18 year age time consent . 2 . Pediatric subject presence document VTE confirm appropriate diagnostic image require anticoagulant therapy least 90 day . 3 . Subjects must receive least 5 day heparin therapy prior randomization treat newly identify index VTE . In addition , prior randomize edoxaban SOC , subject initially treat VKA recommend international normalized ratio ( INR ) &lt; 2.0 . 4 . Subject and/or parent ( ) /legal guardian ( ) legally acceptable representative inform provide signed consent child participate study . 5 . Female subject menarche must test negative pregnancy Screening must consent avoid become pregnant use approved contraception method throughout study . 1 . Subjects active bleeding high risk bleed contraindicate treatment LMWH , SP Xa inhibitor , VKAs , direct oral anticoagulant ( DOACs ; identify high risk bleed prior experimental administration DOACs ) . 2 . Subjects treat thrombolytic agent , thrombectomy insertion caval filter newly identify index VTE . 3 . Administration antiplatelet therapy contraindicate arm except low dose aspirin define 15 mg/Kg/day maximum 100 mg/day . 4 . Subjects hepatic disease associate coagulopathy lead clinically relevant bleeding risk ( aPTT &gt; 50 second international normalized ratio [ INR ] &gt; 2.0 related anticoagulation therapy ) alanine aminotransferase ( ALT ) &gt; 5 × upper limit normal ( ULN ) total bilirubin &gt; 2 × ULN direct bilirubin &gt; 20 % total Screening Visit . 5 . Subjects glomerular filtration rate ( GFR ) &lt; 30 % normal age size determine Schwartz formula . 6 . Subjects stage 2 hypertension define blood pressure ( BP ) systolic and/or diastolic confirm &gt; 99th percentile + 5 mmHg . 7 . Subject thrombocytopenia &lt; 50 × 109/L Screening Visit . Subjects history heparininduced thrombocytopenia may enrol study Investigator 's discretion . 8 . Life expectancy less expect study treatment duration ( 3 month ) . 9 . Subjects know pregnant breastfeeding . 10 . Subjects condition , judge Investigator , would place subject increase risk harm he/she participate study .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Pediatric</keyword>
	<keyword>Venous thrombolism</keyword>
	<keyword>Pulmonary embolism</keyword>
</DOC>